X-Therma pioneers a ground-breaking cold chain platform via a proprietary biopreservation technology, to bring living vaccines, IVF, cell & gene therapies, engineered tissues, and organs to patients off-the-shelf, unleashing the grand potential of all regenerative medicines.
Knowledge from over 4 Billion Years of Nature
Inspired by nature, X-Therma has developed a novel biomimetic molecule, a so-called peptoid, that allows cells and organs to be stored at high subzero temperatures while avoiding possible changes in functionality and viability. The peptoid prevents recrystallization by preventing the process of physical changes resulting from temperature changes.
Chemically defined Safe & Effective Cryopreservation
XT-Thrive® proprietary cryopreservation media is intended for cryopreservation of cell and gene therapies for regenerative medicine applications in ultra-low temperature environments (-70° C to -196° C). XT-Thrive® successfully replaces toxic DMSO solutions in cryopreservation and solves legacy bottlenecks in cell & gene therapy scale-up of cGMP production. Without DMSO and unknown components like serums, it doesn't compromise performance.
Transforming Global Accessibility to Organ Transplantation
X-Therma is building organ preservation and transport technology, that was recently designated as a Breakthrough Device by the FDA. With this technology, X-Therma aims to break down barriers in obtaining life-saving organs and medicine, creating health liberation for all patients in need. The critical extension of the transplantation window by the XT-ViVo® and TimeSeal® Breakthrough Device saves the mass of organs not utilized today (80%) and enables xeno-/engineered-organs.
X-Therma inc., a venture-backed biotech company is headquartered in Richmond, San Francisco Bay Area, with research centers in Richmond and Berkeley, and has expanded to Austria in Europe. X-Therma has been a selected Industrial User at the Lawrence Berkeley National Laboratory and received over $11M in contracts and grant support from the U.S. Department of Defense, the National Science Foundation, and the California Institute for Regenerative Medicine. The company recently closed an oversubscribed Series A of $13M.
PRODUCTS AND SERVICES
Learn how XT-ViVo & TimeSeal will enable multi-day preservation and remove time from the equation.
XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C). Designed and manufactured with the utmost quality in mind, XT-Thrive® is tailored to provide high cell recovery and functionality. It is a non-toxic & hyper-effective alternative to traditional cryopreservatives and is plug and play for cell & tissue manufacturing processes.
Learn about a completely defined, non-toxic cryopreservation solution ideal for cell & gene therapy and cell banking applications at ultra-low temperatures (-70°Cto-196°C).
Learn the key benefits of a proprietary cryopreservation media intended for preserving cell and gene therapies for regenerative medicine applications.
Director of the Diabetes Research Institute Dr. Camillo Ricordi and X-Therma CEO Xiaoxi Wei discuss advancements in type 1 diabetes treatments and the limitations of traditional cryopreservation.
Cryopreservation is a complex undertaking and one that requires a thorough understanding of the product’s critical quality attributes and the variables that may impact them.
Mark Kline, Founder and CTO of X-Therma, describes his entrepreneurial journey, the chemistry breakthroughs achieved in the eight years since X-Therma's launch, and the exciting future of the company.
Next-generation, DMSO-free, serum-free cryoprotectants may offer the answer to enabling more widespread regenerative medicine development and commercialization.
What challenges do outdated cryopreservation techniques raise for companies attempting to shorten the timeline between discovery and clinical implementation to meet the demand for CGT therapies?
Learn about a next-generation cryoprotectant agent carving a new path to accelerate optimal treatments for patients in the overall field of biologics.
Explore the testing of novel cryoprotectants inspired by natural antifreeze protein structure on hematopoietic cells that can replace the use of dimethyl sulfoxide (DMSO).
Learn about technology being developed to increase time for donated organs to reach their recipients using a chemically derived solution that mimics naturally occurring processes in plants and animals.
Explore current cryopreservation limitations and solutions, such as a new type of cryoprotectant inspired by nature that provides a safer alternative to traditional chemicals.
As “living treatments” continue to play an increasingly significant role in medicine, finding cryopreservation approaches that offer an alternative to toxic, suboptimal solvents is critical.
As concerns involving the use of DMSO as a cryoprotectant grow, researchers and contract development and manufacturing organizations (CDMOs) have begun pursuing non-toxic and process-friendly alternatives.
Listen to a discussion about the latest developments in cryopreservation technologies and their implications for clinical implementation.